Role of CDKN2A deletion in grade 2/3 IDH-mutant astrocytomas: need for selective approach in resource-constrained settings.

Suman, Shalini; Sharma, Ravi; Katiyar, Varidh; Mahajan, Swati; Suri, Ashish; Sharma, Mehar C; Sarkar, Chitra; Suri, Vaishali

Suman, Shalini; Sharma, Ravi; Katiyar, Varidh; Mahajan, Swati; Suri, Ashish; Sharma, Mehar C; Sarkar, Chitra; Suri, Vaishali.

Afiliação

Suman S; 1Neuropathology Laboratory, and.
Sharma R; 2Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India.
Katiyar V; 2Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India.
Mahajan S; 1Neuropathology Laboratory, and.
Suri A; 2Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India.
Sharma MC; 1Neuropathology Laboratory, and.
Sarkar C; 1Neuropathology Laboratory, and.
Suri V; 1Neuropathology Laboratory, and.

Neurosurg Focus ; 53(6): E17, 2022 12.

Article em En | MEDLINE | ID: mdl-36455270

Assuntos

Astrocitoma; Glioma; Humanos; Anaplasia; Hibridização in Situ Fluorescente; Astrocitoma/genética; Intervalo Livre de Progressão; Inibidor p16 de Quinase Dependente de Ciclina/genética

Palavras-chave

CDKN2A deletion; IDH-mutant astrocytoma; WHO 2021 classification; glioma; p16 loss

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Astrocitoma / Glioma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google